Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC

[1]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[2]  U. Dafni,et al.  VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study , 2022, Annals of Oncology.

[3]  M. Kris,et al.  Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Chella,et al.  Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial , 2021, The Lancet.

[5]  M. Kent,et al.  1158P Real-world adjuvant treatment patterns and survival outcomes among early NSCLC US patients , 2021, Annals of Oncology.

[6]  M. Tsuboi,et al.  Surgical perspective on neoadjuvant immunotherapy in non-small cell lung cancer. , 2021, The Annals of thoracic surgery.

[7]  A. Spira,et al.  Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non‐small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real‐world retrospective observational study , 2021, Thoracic cancer.

[8]  A. Chella,et al.  IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). , 2021, Journal of Clinical Oncology.

[9]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[10]  E. Feuer,et al.  The Effect of Advances in Lung-Cancer Treatment on Population Mortality. , 2020, The New England journal of medicine.

[11]  Xiaodong Yang,et al.  Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades , 2019, Cancer management and research.

[12]  F. Barlesi,et al.  Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. , 2018, Lung cancer.

[13]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  C. Presley,et al.  The Treatment of Advanced Lung Cancer in the Elderly: The Role of a Comprehensive Geriatric Assessment and Doublet Chemotherapy , 2015, Cancer journal.

[15]  Nikki M. Carroll,et al.  Validating Billing/Encounter Codes as Indicators of Lung, Colorectal, Breast, and Prostate Cancer Recurrence Using 2 Large Contemporary Cohorts , 2014, Medical care.

[16]  Sarah Burdett,et al.  Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data , 2014, The Lancet.

[17]  Fumihiro Tanaka,et al.  Recurrence after surgery in patients with NSCLC. , 2014, Translational lung cancer research.

[18]  Bing Li,et al.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. , 2011, American journal of epidemiology.

[19]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  P. Pairolero,et al.  Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. , 2007, The Annals of thoracic surgery.

[21]  P. Pairolero,et al.  Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. , 2006, The Annals of thoracic surgery.

[22]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .